Search

Your search keyword '"Harbeck, Nadia"' showing total 17 results
Start Over Author "Harbeck, Nadia" Publication Type Conference Materials
17 results on '"Harbeck, Nadia"'

1. Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

Author

Dettorre, Gino M., primary, Dolly, Saoirse, additional, Loizidou, Angela, additional, Chester, John, additional, Jackson, Amanda, additional, Mukherjee, Uma, additional, Zambelli, Alberto, additional, Aguilar-Company, Juan, additional, Bower, Mark, additional, Sng, Christopher C. T., additional, Salazar, Ramon, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Mesia, Ricard, additional, Sita-Lumsden, Ailsa, additional, Seguí, Elia, additional, Biello, Federica, additional, Generali, Daniele, additional, Grisanti, Salvatore, additional, Seeva, Pavetha, additional, Rizzo, Gianpiero, additional, Libertini, Michela, additional, Maconi, Antonio, additional, Moss, Charlotte, additional, Russell, Beth, additional, Tabernero, Josep, additional, Harbeck, Nadia, additional, Vincenzi, Bruno, additional, Bertulli, Rossella, additional, Ottaviani, Diego, additional, Marrari, Andrea, additional, Carmona-García, M. Carmen, additional, Chopra, Neha, additional, Tondini, Carlo, additional, Mirallas, Oriol, additional, Tovazzi, Valeria, additional, Fotia, Vittoria, additional, Cruz, Claudia A., additional, Saoudi-Gonzalez, Nadia, additional, Felip, Eudald, additional, Scotti, Lorenza, additional, Lee, Alvin J. X., additional, Newsom-Davis, Thomas, additional, Patriarca, Andrea, additional, Rimassa, Lorenza, additional, Santoro, Armando, additional, Gennari, Alessandra, additional, Van Hemelrijck, Mieke, additional, Diamantis, Nikolaos, additional, and Pinato, David J., additional

Published
2021
Full Text
View/download PDF

2. Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

Author

O'Shaughnessy, Joyce, primary, Schwartzberg, Lee, additional, Piccart, Martine, additional, Rugo, Hope S., additional, Yardley, Denise A, additional, Cortes, Javier, additional, Untch, Michael, additional, Harbeck, Nadia, additional, Wright, Gail S., additional, Bondarenko, Igor, additional, Glaspy, John, additional, Nowecki, Zbigniew, additional, Kayali, Fadi, additional, Chan, Arlene, additional, Levy, Christelle, additional, Liu, Mei-Ching, additional, Kim, Sung-Bae, additional, Lemieux, Julie, additional, Manikhas, Alexey, additional, Tolaney, Sara, additional, Lim, Elaine, additional, Gombos, Andrea, additional, Stradella, Agostina, additional, Pegram, Mark, additional, Fasching, Peter, additional, Mangel, Laszlo, additional, Semiglazov, Vladimir, additional, Dieras, Veronique, additional, Gianni, Luca, additional, Danso, Michael A, additional, Vacirca, Jeff, additional, Kroll, Stew, additional, O'Connell, Joseph, additional, Tang, Kevin, additional, Wei, Thomas, additional, and Seidman, Andrew, additional

Published
2021
Full Text
View/download PDF

3. Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer

Author

Hurvitz, Sara, primary, Vahdat, Linda, additional, Harbeck, Nadia, additional, Wolff, Antonio C., additional, Tolaney, Sara M., additional, Loi, Sherene, additional, Masuda, Norikazu, additional, O’Shaughnessy, Joyce, additional, Dong, Cassie, additional, Walker, Luke, additional, Rustia, Evelyn, additional, and Borges, Virginia F., additional

Published
2021
Full Text
View/download PDF

4. Abstract PS10-28: Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: HTA-driven analyses from the ExteNET study

Author

Lüftner, Diana, primary, Tesch, Hans, additional, Schmidt, Marcus, additional, Hartkopf, Andreas, additional, Streicher, Sarah, additional, Resch, Anna, additional, Genovese, Luca, additional, Rosé, Christian, additional, Valenti, Roberta, additional, and Harbeck, Nadia, additional

Published
2021
Full Text
View/download PDF

5. Abstract P6-04-01: A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer

Author

Robertson, John FR, primary, Evans, Abigail, additional, Henschen, Stephan, additional, Kirwan, Cliona, additional, Jahan, Ali, additional, Kenny, Laura, additional, Dixon, J. Michael, additional, Schmid, Peter, additional, Kothari, Ashutosh, additional, Mohamed, Omar, additional, Fasching, Peter A, additional, Cheung, Kwok-Leung, additional, Wuerstlein, Rachel, additional, Carroll, Danielle, additional, Klinowska, Teresa, additional, Lindemann, Justin PO, additional, MacDonald, Alexander, additional, Mather, Richard, additional, Maudsley, Rhiannon, additional, Moschetta, Michele, additional, Nikolaou, Myria, additional, Roudier, Martine P, additional, Sarvotham, Tinnu, additional, Schiavon, Gaia, additional, Zhou, Diansong, additional, Zhou, Li, additional, and Harbeck, Nadia, additional

Published
2020
Full Text
View/download PDF

7. Abstract OT2-02-02: MONARCH E: A phase 3 study of standard adjuvant endocrine therapy with or without abemaciclib in patients with high risk, node positive, hormone-receptor positive, human epidermal growth factor receptor 2-negative early-stage breast cancer

Author

Rastogi, Priya, primary, Toi, Masakazu, additional, Martin, Miguel, additional, O'Shaughnessy, Joyce, additional, Headley, Desiree, additional, Wei, Jennifer, additional, Cox, Joanne, additional, Harbeck, Nadia, additional, and Johnston, Stephen, additional

Published
2020
Full Text
View/download PDF

8. Abstract OT1-08-09: CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

Author

O'Shaughnessy, Joyce, primary, Piccart, Martine, additional, Schwartzberg, Lee, additional, Cortes, Javier, additional, Harbeck, Nadia, additional, Im, Seock-Ah, additional, Rugo, Hope, additional, Untch, Michael, additional, Yardley, Denise, additional, Bondarenko, Igor, additional, Dieras, Veronique, additional, Pegram, Mark, additional, Kroll, Stew, additional, O'Connell, Joseph, additional, Vacirca, Jeff, additional, Wei, Thomas, additional, Tang, Kevin, additional, and Seidman, Andrew, additional

Published
2020
Full Text
View/download PDF

9. Abstract OT3-14-02: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy - Precycle

Author

Degenhardt, Tom, primary, Fasching, Peter, additional, Luftner, Diana, additional, Mueller, Volkmar, additional, Thomssen, Christoph, additional, Schem, Christian, additional, Witzel, Isabel, additional, Decker, Thomas, additional, Tesch, Hans, additional, Kuemmel, Sherko, additional, Uleer, Christoph, additional, Wuerstlein, Rachel, additional, Riese, Christoph, additional, Schinköthe, Timo, additional, Kates, Ronald, additional, Schumacher, Johannes, additional, Harbeck, Nadia, additional, and Schmidt, Marcus, additional

Published
2020
Full Text
View/download PDF

10. Abstract OT2-04-03: Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL

Author

Loi, Sherene, primary, McArthur, Heather, additional, Harbeck, Nadia, additional, Pusztai, Lajos, additional, Delaloge, Suzette, additional, Letrent, Kristen, additional, Chen, Tian, additional, Li, Bin, additional, Tatsuoka, Kay, additional, Zardavas, Dimitrios, additional, and Curigliano, Giuseppe, additional

Published
2020
Full Text
View/download PDF

11. Abstract P4-01-01: Presence of circulating tumor cells in high-risk early breast cancer do not predict site of metastatic lesions - Results of the SUCCESS A trial

Author

Trapp, Elisabeth Katharina, primary, Fasching, Peter A, additional, Fehm, Tanja, additional, Schneeweiss, Andreas, additional, Mueller, Volkmar, additional, Harbeck, Nadia, additional, Lorenz, R., additional, Schumacher, Claudia, additional, Heinrich, Georg, additional, deGregorio deGregorio, Amelie, additional, Tzschaschel, Marie, additional, Bekes, Inga, additional, Scholz, Christoph, additional, Rack, Brigitte, additional, Janni, Wolfgang, additional, and Friedl, Thomas WP, additional

Published
2020
Full Text
View/download PDF

12. Abstract CT141: Genetic landscape of premenopausal HR+/HER2- advanced breast cancer (ABC) based on comprehensive circulating tumor DNA analysis and association with clinical outcomes in the Phase III MONALEESA-7 trial

Author

Bardia, Aditya, primary, Su, Faye, additional, Solovieff, Nadia, additional, Im, Seock-Ah, additional, Sohn, Joohyuk, additional, Lee, Keun Seok, additional, Campos-Gomez, Saul, additional, Jung, Kyung Hae, additional, Vazquez, Rafael Villanueva, additional, Lu, Yen-Shen, additional, Franke, Fabio, additional, Hurvitz, Sara, additional, Harbeck, Nadia, additional, Chow, Louis, additional, Lorenc, Karen Rodriguez, additional, Taran, Tetiana, additional, Babbar, Naveen, additional, and Tripathy, Debu, additional

Published
2019
Full Text
View/download PDF

13. Abstract P5-19-01: Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1

Author

Harbeck, Nadia, primary, Huang, Chiun-Sheng, additional, Hurvitz, Sara, additional, Yeh, Dah-Cherng, additional, Shao, Zhimin, additional, Im, Seock-Ah, additional, Jung, Kyung Hae, additional, Shen, Kunwei, additional, Ro, Jungsil, additional, Jassem, Jacek, additional, Zhang, Qingyuan, additional, Im, Young-Hyuck, additional, Wojtukiewicz, Marek, additional, Sun, Qiang, additional, Chen, Shin-Cheh, additional, Goeldner, Rainer-Georg, additional, Lahogue, Annick, additional, Uttenreuther-Fischer, Martina, additional, Xu, Binghe, additional, and Piccart-Gebhart, Martine, additional

Published
2015
Full Text
View/download PDF

14. Abstract P4-11-01: Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial

Author

Nitz, Ulrike, primary, Gluz, Oleg, additional, Kates, Ronald E, additional, Hofmann, Daniel, additional, Kreipe, Hans H, additional, Christgen, Matthias, additional, Shak, Steve, additional, Clemens, Michael, additional, Kraemer, Stefan, additional, Aktas, Bahriye, additional, Kuemmel, Sherko, additional, Reimer, Toralf, additional, Kusche, Manfred, additional, Heyl, Volker, additional, Lorenz-Salehi, Fatemah, additional, Just, Marianne, additional, Liedtke, Cornelia, additional, Wuerstlein, Rachel, additional, and Harbeck, Nadia, additional

Published
2015
Full Text
View/download PDF

15. Abstract OT2-2-01: tnAcity: A phase II/III trial ofnab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)

Author

Yardley, Denise A, primary, Coleman, Robert E, additional, Conte, Pierfranco, additional, O'Shaughnessy, Joyce, additional, Cortes, Javier, additional, Glück, Stefan, additional, Brufsky, Adam, additional, Nabholtz, Jean-Marc A, additional, Li, Li, additional, Miller, JulieAnn, additional, Barton, Debora, additional, and Harbeck, Nadia, additional

Published
2015
Full Text
View/download PDF

16. Abstract P2-10-05: eHealth in modern breast cancer treatment: New possibilities in communication between patients, doctors and nursing staff

Author

Wuerstlein, Rachel, primary, Kirkovits, Thomas, additional, Drewes, Caroline, additional, Schiltz, Daniel, additional, Bauerfeind, Ingo, additional, Haidinger, Renate, additional, Paradies, Kerstin, additional, Goldmann-Posch, Ursula, additional, Schinkoethe, Timo, additional, and Harbeck, Nadia, additional

Published
2015
Full Text
View/download PDF

17. Second international consensus guidelines for breast cancer in young women (BCY2).

Author

Paluch-Shimon, Shani, Pagani, Olivia, Partridge, Ann H., Bar-Meir, Eran, Fallowfield, Lesley, Fenlon, Deborah, Friedman, Eitan, Gelmon, Karen, Gentilini, Oreste, Geraghty, James, Harbeck, Nadia, Higgins, Stephen, Loibl, Sibylle, Moser, Elizabeth, Peccatori, Fedro, Raanani, Hila, Kaufman, Bella, and Cardoso, Fatima

Subjects
BREAST cancer conferences, YOUNG women, CONFERENCES & conventions, EVIDENCE-based medicine, HEALTH
Abstract

The 2nd International Consensus Conference for Breast Cancer in Young Women (BCY2) took place in November 2014, in Dublin, Ireland organized by the European School of Oncology (ESO). Consensus recommendations for the management of breast cancer in young women (BCYW) were updated from BCY1 with incorporation of new evidence to inform the guidelines, and areas of research priorities were identified. This manuscript summarizes these international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA). [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results